Quality Policy- Management and Identification of Particulates in Product Retains

What this document is for

In the lifecycle management of pharmaceutical products, the presence of unexpected particulates represents a critical quality attribute that directly impacts patient safety and product integrity.

The full text is not reproduced here. Preview any document free on the catalog page, then buy the complete catalog in your language.

Ships as

Grounded in

FDA 21 CFR 210/211 and Part 11, EU GMP (EudraLex Volume 4, including Annex 1 and Annex 11), ICH Q7–Q12, and WHO GMP. Supplied in 13 languages.

Other Quality Systems documents

• Categorization and Handling of Potent Compounds
• Elevated Surfaces and Fall Protection
• Hearing Conservation Program
• Medical Surveillance and Occupational Health Program
• Protective Eyewear and Footwear Compliance
• Fixed Machine Safeguarding and Guarding Compliance
• Safe Handling and Maintenance of Compressed Gas and Air Systems
• Access and Utilization of Pharmaceutical Compendia